BIOXYNE ORD
Bioxyne Receives $1.7m Funding from Scottish Government Agency for UK Medicinal Cannabis Manufacturing Facility
Bioxyne (ASX: BXN) subsidiary Breathe Life Sciences UK has received approximately $1.7 million in funding from economic development agency South of Scotland Enterprise (SOSE) to establish its UK medicinal cannabis manufacturing and distribution facility.
Bioxyne earns international GMP certification, strikes $5.6m German API supply deal
Bioxyne (ASX: BXN) has received certificates of Good Manufacturing Practice (GMP) compliance under mutual recognition agreements with five countries. The company’s wholly owned subsidiary Breathe Life Sciences – a GMP-licensed manufacturer, wholesaler, importer and exporter of controlled substances including medicinal cannabis, psilocybin and MDMA – earned the certification. Agreements with Singapore, the European Union, Canada, […]
Bioxyne upgrades FY25 outlook by $3m to $28m on rising demand for psychedelic drug therapies
Diversified health products company Bioxyne (ASX: BXN) has upgraded its full-year revenue guidance for financial year 2025 by $3 million to $28m. The upgrade follows reported revenue of $12.6m for the first six months of the year, which represents a 267% increase on the previous corresponding period (pcp). Bioxyne is forecasting revenue of $15.4m for […]
Bioxyne recruits distributor for developing Asian markets ahead of Malaysia, China push
Health products company Bioxyne (ASX: BXN) has extended its reach into more Asian markets after inking a distribution deal with Dato Louis Chong group marketing company ASVA International to sell its Bioxyne products in Thailand, Philippines, Myanmar, Cambodia and the African gateway country, Mauritius. Bioxyne started its push into Asia last year, launching three health-and-beauty […]
